Intellia, Morgan Stanley

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11. The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment,
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal weight rating in a report published on Monday morning, MarketBeat.com reports.
Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset
Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran.
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now
Morgan Stanley cuts Intellia stock rating amid gene editing concerns
Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also significantly reduced its price target to $11.
bovnews1d
Intellia Therapeutics Inc (NTLA) Posted -1212.19% Profit Margin Last Year—Can It Hold Up?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.99 which represents a decrease of $-0.30 or -2.66% from the prior close of $11.29. The stock opened at $11.25 and touched a ...
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
bovnews7d
What’s Driving Intellia Therapeutics Inc (NTLA) Stock’s -29.00% Plunge Over the Past Month?
Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...
The Business Journals19d
Intellia cuts 27% of workforce as it eyes commercial launch
CEO John Leonard said the company will focus its resources largely on two late-stage programs amid a “challenging market environment.” Intellia Therapeutics Inc. is shedding employees and ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.
BMO Capital Markets Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...
Nasdaq6d
Intellia Therapeutics Doses First Patient in Global Phase 3 Study of NTLA-2002 for Hereditary Angioedema Treatment
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
ATTENTION Intellia Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...